Common Stocks - 98.3%
|
|||
Shares
|
Value ($)
|
||
Biotechnology - 20.4%
|
|||
Biotechnology - 20.4%
|
|||
Acelyrin, Inc.
|
900,000
|
3,708,000
|
|
Acumen Pharmaceuticals, Inc. (a)
|
1,140,000
|
3,351,600
|
|
Allogene Therapeutics, Inc. (a)(b)
|
4,088,900
|
10,222,250
|
|
Alnylam Pharmaceuticals, Inc. (a)
|
540,000
|
80,152,200
|
|
Apogee Therapeutics, Inc.
|
52,600
|
2,400,664
|
|
Arcellx, Inc. (a)
|
400,000
|
20,800,000
|
|
Arcus Biosciences, Inc. (a)
|
700,000
|
10,549,000
|
|
Argenx SE ADR (a)
|
280,000
|
103,885,600
|
|
Ascendis Pharma A/S sponsored ADR (a)
|
820,000
|
110,782,000
|
|
Avidity Biosciences, Inc. (a)
|
1,000,000
|
26,860,000
|
|
Blueprint Medicines Corp. (a)
|
700,000
|
73,892,000
|
|
Cargo Therapeutics, Inc. (b)
|
995,805
|
18,920,295
|
|
Caris Life Sciences, Inc. (a)(c)(d)
|
1,420,479
|
3,679,041
|
|
Celldex Therapeutics, Inc. (a)
|
550,000
|
18,315,000
|
|
Cytokinetics, Inc. (a)(b)
|
1,480,000
|
71,794,800
|
|
Exact Sciences Corp. (a)
|
1,782,525
|
81,015,761
|
|
Immunocore Holdings PLC ADR (a)(b)
|
391,904
|
19,195,458
|
|
Insmed, Inc. (a)
|
500,000
|
27,525,000
|
|
Intellia Therapeutics, Inc. (a)(b)
|
560,000
|
11,972,800
|
|
Janux Therapeutics, Inc. (a)
|
650,000
|
34,775,000
|
|
Keros Therapeutics, Inc. (a)
|
650,000
|
30,465,500
|
|
Legend Biotech Corp. ADR (a)
|
2,500,000
|
100,025,000
|
|
Merus BV (a)(b)
|
640,000
|
34,073,600
|
|
Morphic Holding, Inc. (a)
|
450,000
|
13,666,500
|
|
Nuvalent, Inc. Class A (a)
|
670,000
|
43,965,400
|
|
Oruka Therapeutics, Inc. (c)(d)(e)
|
1,451,092
|
8,619,777
|
|
Poseida Therapeutics, Inc. (a)
|
2,375,621
|
7,103,107
|
|
Regeneron Pharmaceuticals, Inc. (a)
|
300,000
|
294,048,000
|
|
Repligen Corp. (a)
|
120,000
|
17,890,800
|
|
Spyre Therapeutics, Inc. (a)
|
500,000
|
17,475,000
|
|
Summit Therapeutics, Inc. (a)(b)
|
1,100,000
|
9,553,500
|
|
Vaxcyte, Inc. (a)
|
1,450,000
|
101,891,500
|
|
Viking Therapeutics, Inc. (a)
|
52,307
|
3,256,634
|
|
Viridian Therapeutics, Inc. (a)
|
1,500,000
|
17,925,000
|
|
Xenon Pharmaceuticals, Inc. (a)
|
1,200,000
|
45,684,000
|
|
Zentalis Pharmaceuticals, Inc. (a)(b)
|
900,000
|
10,692,000
|
|
1,490,131,787
|
|||
Health Care Equipment & Supplies - 25.6%
|
|||
Health Care Equipment - 25.6%
|
|||
Boston Scientific Corp. (a)
|
10,500,000
|
793,485,000
|
|
Edwards Lifesciences Corp. (a)
|
1,250,000
|
108,612,500
|
|
Glaukos Corp. (a)
|
1,000,000
|
112,720,000
|
|
Inspire Medical Systems, Inc. (a)(b)
|
485,000
|
77,013,150
|
|
Insulet Corp. (a)
|
700,000
|
124,033,000
|
|
Intuitive Surgical, Inc. (a)
|
305,000
|
122,646,600
|
|
Masimo Corp. (a)
|
850,000
|
105,825,000
|
|
Medical Microinstruments, Inc. warrants 2/16/31 (a)(c)(d)
|
15,815
|
195,790
|
|
Penumbra, Inc. (a)
|
1,278,503
|
242,237,963
|
|
PROCEPT BioRobotics Corp. (a)(b)
|
640,000
|
42,496,000
|
|
Stryker Corp.
|
400,000
|
136,436,000
|
|
1,865,701,003
|
|||
Health Care Providers & Services - 21.7%
|
|||
Health Care Facilities - 1.4%
|
|||
Surgery Partners, Inc. (a)
|
3,600,000
|
99,360,000
|
|
Health Care Services - 8.3%
|
|||
agilon health, Inc. (a)(b)
|
10,280,000
|
64,764,000
|
|
BrightSpring Health Services, Inc. (b)
|
2,850,000
|
32,062,500
|
|
Cigna Group
|
700,000
|
241,234,000
|
|
CVS Health Corp.
|
2,450,000
|
146,020,000
|
|
LifeStance Health Group, Inc. (a)
|
9,000,000
|
50,130,000
|
|
Privia Health Group, Inc. (a)
|
4,080,000
|
70,869,600
|
|
605,080,100
|
|||
Managed Health Care - 12.0%
|
|||
Alignment Healthcare, Inc. (a)
|
5,600,000
|
44,128,000
|
|
Centene Corp. (a)
|
1,960,000
|
140,316,400
|
|
Molina Healthcare, Inc. (a)
|
125,000
|
39,322,500
|
|
UnitedHealth Group, Inc.
|
1,320,000
|
653,888,400
|
|
877,655,300
|
|||
TOTAL HEALTH CARE PROVIDERS & SERVICES
|
1,582,095,400
|
||
Health Care Technology - 2.0%
|
|||
Health Care Technology - 2.0%
|
|||
Evolent Health, Inc. Class A (a)
|
1,500,000
|
31,785,000
|
|
Phreesia, Inc. (a)
|
1,449,451
|
27,423,613
|
|
Veeva Systems, Inc. Class A (a)
|
480,000
|
83,640,000
|
|
142,848,613
|
|||
Life Sciences Tools & Services - 11.5%
|
|||
Life Sciences Tools & Services - 11.5%
|
|||
10X Genomics, Inc. (a)
|
1,982,656
|
44,451,148
|
|
10X Genomics, Inc. Class B (a)(f)
|
500,000
|
11,210,000
|
|
Bruker Corp.
|
940,000
|
61,579,400
|
|
Danaher Corp.
|
1,900,000
|
487,920,000
|
|
IQVIA Holdings, Inc. (a)
|
370,000
|
81,063,300
|
|
Lonza Group AG
|
67,000
|
36,370,997
|
|
Thermo Fisher Scientific, Inc.
|
208,000
|
118,139,840
|
|
840,734,685
|
|||
Pharmaceuticals - 17.1%
|
|||
Pharmaceuticals - 17.1%
|
|||
AstraZeneca PLC (United Kingdom)
|
800,000
|
124,359,226
|
|
Edgewise Therapeutics, Inc. (a)
|
560,000
|
9,592,800
|
|
Eli Lilly & Co.
|
760,000
|
623,458,400
|
|
Enliven Therapeutics, Inc. (a)
|
500,000
|
11,285,000
|
|
Merck & Co., Inc.
|
2,480,000
|
311,339,200
|
|
Pharvaris BV (a)
|
738,455
|
14,001,107
|
|
Royalty Pharma PLC
|
2,400,000
|
65,784,000
|
|
Structure Therapeutics, Inc. ADR (a)
|
650,000
|
22,230,000
|
|
UCB SA
|
500,000
|
70,135,384
|
|
1,252,185,117
|
|||
TOTAL COMMON STOCKS
(Cost $4,568,111,515)
|
7,173,696,605
|
||
Convertible Preferred Stocks - 1.3%
|
|||
Shares
|
Value ($)
|
||
Biotechnology - 0.6%
|
|||
Biotechnology - 0.6%
|
|||
Asimov, Inc. Series B (a)(c)(d)
|
101,438
|
4,551,523
|
|
Caris Life Sciences, Inc. Series D (a)(c)(d)
|
3,206,021
|
8,303,594
|
|
Cleerly, Inc. Series C (a)(c)(d)
|
1,285,367
|
13,817,695
|
|
Element Biosciences, Inc. Series C (a)(c)(d)
|
572,265
|
5,184,721
|
|
ElevateBio LLC Series C (a)(c)(d)
|
254,900
|
779,994
|
|
Endeavor BioMedicines, Inc. Series C (c)(d)
|
1,366,212
|
8,907,702
|
|
Inscripta, Inc. Series E (a)(c)(d)
|
1,282,228
|
3,846,684
|
|
45,391,913
|
|||
Financial Services - 0.2%
|
|||
Diversified Financial Services - 0.1%
|
|||
Thriveworks TopCo LLC Series B (a)(c)(d)(g)
|
473,270
|
4,746,898
|
|
Specialized Finance - 0.1%
|
|||
Saluda Medical, Inc. Series E (a)(c)(d)
|
1,155,359
|
8,052,852
|
|
TOTAL FINANCIAL SERVICES
|
12,799,750
|
||
Health Care Equipment & Supplies - 0.1%
|
|||
Health Care Equipment - 0.1%
|
|||
Medical Microinstruments, Inc. Series C (c)(d)
|
316,310
|
10,343,337
|
|
Health Care Providers & Services - 0.0%
|
|||
Health Care Services - 0.0%
|
|||
dMed Biopharmaceutical Co. Ltd. Series C (a)(c)(d)
|
380,451
|
1,807,142
|
|
Health Care Technology - 0.3%
|
|||
Health Care Technology - 0.3%
|
|||
Aledade, Inc.:
|
|||
Series B1 (a)(c)(d)
|
201,220
|
7,928,068
|
|
Series E1 (a)(c)(d)
|
56,664
|
2,232,562
|
|
Omada Health, Inc. Series E (a)(c)(d)
|
2,153,073
|
8,676,884
|
|
Wugen, Inc. Series B (a)(c)(d)
|
454,342
|
1,744,673
|
|
20,582,187
|
|||
Pharmaceuticals - 0.1%
|
|||
Pharmaceuticals - 0.1%
|
|||
Galvanize Therapeutics Series B (a)(c)(d)
|
3,696,429
|
3,141,965
|
|
TOTAL CONVERTIBLE PREFERRED STOCKS
(Cost $155,912,683)
|
94,066,294
|
||
Convertible Bonds - 0.2%
|
|||
Principal
Amount (h)
|
Value ($)
|
||
Health Care Equipment & Supplies - 0.2%
|
|||
Health Care Supplies - 0.2%
|
|||
Kardium, Inc. 10% 12/31/26 (c)(d)
|
12,154,428
|
12,154,428
|
|
Pharmaceuticals - 0.0%
|
|||
Pharmaceuticals - 0.0%
|
|||
Galvanize Therapeutics 6% 2/28/27 (c)(d)
|
3,306,100
|
3,389,744
|
|
TOTAL CONVERTIBLE BONDS
(Cost $15,460,528)
|
15,544,172
|
||
Money Market Funds - 1.6%
|
|||
Shares
|
Value ($)
|
||
Fidelity Cash Central Fund 5.39% (i)
|
36,914,878
|
36,922,261
|
|
Fidelity Securities Lending Cash Central Fund 5.39% (i)(j)
|
83,035,379
|
83,043,683
|
|
TOTAL MONEY MARKET FUNDS
(Cost $119,964,194)
|
119,965,944
|
||
TOTAL INVESTMENT IN SECURITIES - 101.4%
(Cost $4,859,448,920)
|
7,403,273,015
|
NET OTHER ASSETS (LIABILITIES) - (1.4)%
|
(102,644,409)
|
NET ASSETS - 100.0%
|
7,300,628,606
|
(a)
|
Non-income producing
|
(b)
|
Security or a portion of the security is on loan at period end.
|
(c)
|
Restricted securities (including private placements) - Investment in securities not registered under the Securities Act of 1933 (excluding 144A issues). At the end of the period, the value of restricted securities (excluding 144A issues) amounted to $122,105,074 or 1.7% of net assets.
|
(d)
|
Level 3 security
|
(e)
|
Security or a portion of the security purchased on a delayed delivery or when-issued basis.
|
(f)
|
Security exempt from registration under Rule 144A of the Securities Act of 1933. These securities may be resold in transactions exempt from registration, normally to qualified institutional buyers. At the end of the period, the value of these securities amounted to $11,210,000 or 0.2% of net assets.
|
(g)
|
Investment is owned by a wholly-owned subsidiary (Subsidiary) that is treated as a corporation for U.S. tax purposes.
|
(h)
|
Amount is stated in United States dollars unless otherwise noted.
|
(i)
|
Affiliated fund that is generally available only to investment companies and other accounts managed by Fidelity Investments. The rate quoted is the annualized seven-day yield of the fund at period end. A complete unaudited listing of the fund's holdings as of its most recent quarter end is available upon request. In addition, each Fidelity Central Fund's financial statements are available on the SEC's website or upon request.
|
(j)
|
Investment made with cash collateral received from securities on loan.
|
Additional information on each restricted holding is as follows:
|
||
Security
|
Acquisition Date
|
Acquisition Cost ($)
|
Aledade, Inc. Series B1
|
5/07/21
|
7,704,855
|
Aledade, Inc. Series E1
|
5/20/22
|
2,822,683
|
Asimov, Inc. Series B
|
10/29/21
|
9,401,345
|
Caris Life Sciences, Inc.
|
10/06/22
|
7,954,682
|
Caris Life Sciences, Inc. Series D
|
5/11/21
|
25,968,770
|
Cleerly, Inc. Series C
|
7/08/22
|
15,142,394
|
dMed Biopharmaceutical Co. Ltd. Series C
|
12/01/20
|
5,403,602
|
Element Biosciences, Inc. Series C
|
6/21/21
|
11,763,880
|
ElevateBio LLC Series C
|
3/09/21
|
1,069,306
|
Endeavor BioMedicines, Inc. Series C
|
4/22/24
|
8,913,987
|
Galvanize Therapeutics Series B
|
3/29/22
|
6,399,572
|
Galvanize Therapeutics 6% 2/28/27
|
2/28/24
|
3,306,100
|
Inscripta, Inc. Series E
|
3/30/21
|
11,322,073
|
Kardium, Inc. 10% 12/31/26
|
5/31/24
|
12,154,428
|
Medical Microinstruments, Inc. warrants 2/16/31
|
2/16/24
|
0
|
Medical Microinstruments, Inc. Series C
|
2/16/24
|
10,543,783
|
Omada Health, Inc. Series E
|
12/22/21
|
12,908,103
|
Oruka Therapeutics, Inc.
|
4/03/24
|
8,619,777
|
Saluda Medical, Inc. Series E
|
4/06/23
|
9,328,137
|
Thriveworks TopCo LLC Series B
|
7/23/21 - 2/25/22
|
13,696,817
|
Wugen, Inc. Series B
|
7/09/21
|
3,523,377
|
Affiliate
|
Value,
beginning
of period ($)
|
Purchases ($)
|
Sales
Proceeds ($)
|
Dividend
Income ($)
|
Realized
Gain (loss) ($)
|
Change in
Unrealized
appreciation
(depreciation) ($)
|
Value,
end
of period ($)
|
% ownership,
end
of period
|
Fidelity Cash Central Fund 5.39%
|
3,213,126
|
131,987,750
|
98,277,343
|
46,158
|
(1,272)
|
-
|
36,922,261
|
0.1%
|
Fidelity Securities Lending Cash Central Fund 5.39%
|
90,247,976
|
225,906,933
|
233,111,226
|
124,717
|
-
|
-
|
83,043,683
|
0.3%
|
Total
|
93,461,102
|
357,894,683
|
331,388,569
|
170,875
|
(1,272)
|
-
|
119,965,944
|
|